参考文献/References:
[1] Daubert C,Behar N,Martins RP,et al. Avoiding non-responders to cardiac resynchronization therapy:a practical guide[J]. Eur Heart J,2017,38(19):1463-1472.
[2] Lopez-Andres N,Rossignol P,Iraqi W,et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure,left ventricular dysfunction,and dyssynchrony:insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial[J]. Eur J Heart Fail,2012,14(1):74-81.
[3] López B,González A,Ravassa S,et al. Circulating biomarkers of myocardial fibrosis:the need for a reappraisal[J]. J Am Coll Cardiol,2015,65(22):2449-2456.
[4] Gehlken C,Suthahar N,Meijers WC,et al. Galectin-3 in heart failure:an update of the last 3 years[J]. Heart Fail Clin,2018,14(1):75-92.
[5] Massoullie G,Sapin V,Ploux S,et al. Low fibrosis biomarker levels predict cardiac resynchronization therapy response[J]. Sci Rep,2019,9(1):6103.
[6] Sokal A,Lenarczyk R,Kowalski O,et al. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy:a subanalysis of the TRUST CRT randomized trial population[J]. Heart Rhythm ,2016,13(5):1088-1095.
[7] Andre C,Piver E,Perault R,et al. Galectin-3 predicts response and outcomes after cardiac resynchronization therapy[J]. J Transl Med,2018,16(1):299.
[8] Mueller C,McDonald K,de Boer RA,et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations[J]. Eur J Heart Fail,2019,21(6):715-731.
[9] Lellouche N,de Diego C,Cesario DA,et al. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy[J]. Am J Cardiol,2007,99(2):242-246.
[10] Brouwers C ,Versteeg H,Meine M,et al. Association between brain natriuretic peptide,markers of inflammation and the objective and subjective response to cardiac resynchronization therapy[J]. Brain Behav Immun,2014,40:211-218.
[11] Debska-Kozlowska A,Ksiazczyk M,Warchol I,et al. Clinical usefulness of N-terminal prohormone of brain natriuretic peptide and high sensitivity troponin T in patients with heart failure undergoing cardiac resynchronization therapy[J]. Curr Pharm Des,2019,25(14):1671-1678.
[12] Bakos Z,Chatterjee NC,Reitan C,et al. Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score[J]. BMC Cardiovasc Disord,2018,18(1):70.
[13] Arrigo M,Truong QA,Szymonifka J,et al. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy[J]. Europace,2017,19(11):1848-1854.
[14] Stenemo M,Ganna A,Salihovic S,et al. The metabolites urobilin and sphingomyelin (30:1) are associated with incident heart failure in the general population[J]. ESC Heart Fail,2019,6(4):764-773.
[15] Lanfear DE,Gibbs JJ,Li J,et al. Targeted metabolomic profiling of plasma and survival in heart failure patients[J]. JACC Heart Fail,2017,5(11):823-832.
[16] Yang S,Hu Y,Zhao J,et al. Comprehensive plasma metabolites profiling reveals phosphatidylcholine species as potential predictors for cardiac resynchronization therapy response[J]. ESC Heart Fail,2021,8(1):280-290.
[17] Zhu MR,Fulati Z,Liu Y,et al. The value of serum metabolomics analysis in predicting the response to cardiac resynchronization therapy[J]. J Geriatr Cardiol,2019,16(7):529-539.
[18] Gong X,Sun Z,Huang Z,et al. Circulating metabolite profiles to predict response to cardiac resynchronization therapy[J]. BMC Cardiovasc Disord,2020,20(1):178.
[19] Padeletti L,Modesti PA,Cartei S,et al. Metabolomic does not predict response to cardiac resynchronization therapy in patients with heart failure[J]. J Cardiovasc Med (Hagerstown),2014,15(4):295-300.
[20] Perge P,Boros AM,Zima E,et al. Hyperuricemia predicts adverse clinical outcomes after cardiac resynchronization therapy[J]. Scand Cardiovasc J,2018,52(5):250-255.
[21] Sunman H,Ozkan A,Yorgun H,et al. Evaluating the effects of cardiac resynchronization therapy on pathophysiological pathways of heart failure using surrogate biomarkers[J]. Cardiol J,2018,25(1):42-51.
[22] Sultan A,Wormann J,Luker J,et al. Significance of myeloperoxidase plasma levels as a predictor for cardiac resynchronization therapy response[J]. Clin Res Cardiol,2021,110(8):1173-1180.
[23] Chatterjee NA,Singh JP,Szymonifka J,et al. Incremental value of cystatin C over conventional renal metrics for predicting clinical response and outcomes in cardiac resynchronization therapy:the BIOCRT study[J]. Int J Cardiol,2016,205:43-49.
[24] Ruan ZB,Chen GC,Ren Y,et al. Prediction efficiency of serum cystatin C for clinical outcome in patients with cardiac resynchronization therapy[J]. Ir J Med Sci,2018,187(4):909-914.
相似文献/References:
[1]黄晓凤 熊峰.超声心动图技术在优化心脏再同步化治疗效果中的应用[J].心血管病学进展,2019,(7):1043.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.020]
HUANG XiaofengXIONG Feng.Application of Echocardiography in Optimizing Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2019,(10):1043.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.020]
[2]胡威,苏芳菊,张卫泽.左室四极导线在心脏再同步化治疗中的应用进展[J].心血管病学进展,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
HU Wei,SU Fangju,ZHANG Weize.Application of Left Ventricular Quadrupole in Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2020,(10):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
[3]熊倩 俞杉.心肌应变成像在CRT评估中的研究进展[J].心血管病学进展,2020,(4):399.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.018]
XIONG QianYU Shan.Myocardial Strain Imaging in C Assessment[J].Advances in Cardiovascular Diseases,2020,(10):399.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.018]
[4]林杰 李海瑞 李海鹰.左束支区域起搏的现状和展望[J].心血管病学进展,2020,(5):462.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.006]
LIN Jie,LI Hairui,LI Haiying.Present and Future of Left Bundle Branch Area Pacing[J].Advances in Cardiovascular Diseases,2020,(10):462.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.006]
[5]陈天欢 李小明.心力衰竭患者心脏再同步化治疗最新进展[J].心血管病学进展,2020,(12):1290.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.016]
CHEN Tianhuan,LI Xiaoming.Cardiac Resynchronization Therapy in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2020,(10):1290.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.016]
[6]陈益帆 周秀娟.希氏束起搏在心力衰竭患者中的临床应用进展[J].心血管病学进展,2021,(1):64.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
CHEN Yifan,ZHOU Xiujuan.Clinical Application of His Bundle Pacing in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2021,(10):64.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[7]苗旺 张楠 王睿.希浦系统起搏在心脏再同步化治疗中的应用[J].心血管病学进展,2021,(8):707.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.009]
MIAO Wang ZHANG Nan WANG Rui.Application of His-Purkinje System Pacing in Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2021,(10):707.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.009]
[8]汪汉 蔡琳邓晓奇 李锦 童琳 刘汉雄.双心室起搏模式下心力衰竭患者的心脏研究[J].心血管病学进展,2022,(4):380.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.022]
WANG Han,CAI lin,DENG Xiaoqi,et al.Cardiac Electromechanical Coupling in Patients with Heart Failure under Biventricular Pacing Mode[J].Advances in Cardiovascular Diseases,2022,(10):380.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.022]
[9]李瑞瑞 李学斌.起搏诱导性心肌病临床研究进展[J].心血管病学进展,2022,(2):133.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.010]
LI RuiruiLI Xuebin.Progress of Clinical Research on Pacing-Induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(10):133.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.010]
[10]陈铳铳 周秀娟.左束支起搏治疗心力衰竭的研究进展[J].心血管病学进展,2022,(2):137.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.011]
CHEN Chongchong,ZHOU Xiujuan.Left Bundle Branch Pacing in the Treatment of Heart Failure[J].Advances in Cardiovascular Diseases,2022,(10):137.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.011]